Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial
Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial
Author
Muangnoicharoen S., Wiangcharoen R., Nanthapisal S., Kamolratakul S., Lawpoolsri S., Jongkaewwattana A., Thitithanyanont A., Luvira V., Chinwangso P., Thanthamnu N., Chantratita N., Lim J.K., Anh Wartel T., Excler J.-L., Ryser M.F., Leong C., Mak T.K., Pitisuttithum P.
Affiliations
Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, 420/6 Ratchawithi Road, Ratchathewi, Bangkok, 10400, Thailand; Phaholpolpayuhasena Hospital, 572 Saeng Chuto Road Muang, Kanchanaburi, 71000, Thailand; Faculty of Medicine, Thammasat University (Rangsit Campus), Pathum Thani, Thailand; Center of Excellence for Biomedical and Public Health Informatics (BIOPHICS), Bangkok, Thailand; Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani, Thailand; Faculty of Science, Mahidol University, Bangkok, Thailand; International Vaccine Institute, Seoul, South Korea; Janssen Global Medical Affairs, Beerse, Belgium; Janssen Asia Pacific Medical Affairs Operations, Sydney, Australia; Centre of Regulatory Excellence, Duke-NUS Medical School and Duke-NUS Global Health Institute, Singapore; Vaccine and Infectious Disease Organization, University of Saskatchewan, Canada
